Tag: Acute myeloid leukemia

How Blood Cancer Cells Rewire to Evade Drug Treatment

October 23, 2024

“[...] drugs that target individual signalling pathways in AML often fail to stop proliferation malignant growth, due to the wide variety, redundancy and cross talk between multiple pathways regulating and… read more

Oncotarget

TP53 Mutated AML: Transplant or No Transplant

October 11, 2024

“In summary, this study reported improved survival when allo-HTC was performed in CR1 versus after later lines of therapy.” BUFFALO, NY- October 11, 2024 – A new editorial was published… read more

Oncotarget

Case for Inflammatory Memory for Hematopoietic Stem and Progenitor Cells in AML Niche

September 5, 2024

“In this research perspective, we discuss recent work from our lab describing an active role of HSPCs in AML and the potential implications.” BUFFALO, NY- September 5, 2024 – A… read more

Oncotarget

Editorial: Genomics Has More to Reveal

July 2, 2024

“If there was any doubt, this discovery demonstrates that genomics, extensively deployed over the past two decades, still has much to reveal to us.” BUFFALO, NY- July 2, 2024 –… read more

Figure 2: Effect of treatment with MIA-602 on the growth of Doxorubicin-resistant K-562 tumors xenographed into nude mice.

Oncotarget

Exploring the Role of MIA-602 in Overcoming Doxorubicin-resistance in Acute Myeloid Leukemia

April 10, 2024

“Our results reveal that MIA-602 may be a useful treatment for Doxorubicin-resistant AML [...]” BUFFALO, NY- April 10, 2024 – A new research paper was published in Oncotarget's Volume 15… read more

Figure 6: Effects of various drug combinations on molecular markers of apoptosis in patient-derived cell samples.

Oncotarget

ABT199/Venetoclax Synergism With Thiotepa in Acute Myeloid Leukemia (AML) Cells

March 25, 2024

“[...] the combination of ABT199/venetoclax and Thio enhances the cytotoxicity of (Flu+Clad+Bu) in AML cell lines and leukemia patient-derived cell samples.” BUFFALO, NY- March 25, 2024 – A new research… read more

Oncotarget

Reductive Carboxylation of Glutamine as a Potential Target in AML

January 16, 2024

“Identification and validation of novel and targetable metabolic weaknesses in AML is ongoing.” BUFFALO, NY- January 16, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on… read more

Oncotarget

C/EBPβ Cooperates With MYB to Maintain the Oncogenic Program of AML Cells

November 13, 2023

“This makes C/EBPβ an interesting pro-oncogenic player in AML, worthy of further studies.” BUFFALO, NY- November 13, 2023 – A new editorial perspective was published in Oncotarget's Volume 14 on… read more

Figure 1: Graphical illustration of the main findings from Pfeiffer et al., Cancer Research, 2022. Combined Inhibition of SHP2 and Mutated RTKs Prevent Acquired Resistance in Leukemia

Oncotarget

Combined Inhibition of SHP2 and Mutated RTKs Prevent Acquired Resistance in Leukemia

November 8, 2023

“In summary, this study reveals a molecular escape mechanism of mutated RTK-driven leukemic cells from SHP2 allosteric inhibition [...]” BUFFALO, NY- November 8, 2023 – A new editorial paper was… read more

Figure 1: Mechanisms of MCL-1 inhibitor-induced MCL-1 protein upregulation, stability, and induction of apoptosis.

Oncotarget

Decoding the Mechanism Behind MCL-1 Inhibitors: A Pathway to Understanding MCL-1 Protein Stability

June 28, 2023

“Taken together, the study provides novel insights into the regulation of MCL-1 expression by MCL1i, associated molecular changes and their implications.” BUFFALO, NY- June 28, 2023 – A new editorial… read more